Literature DB >> 10092084

Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation.

P Devaux1, D Christiansen, M Fontaine, D Gerlier.   

Abstract

C3b and C5b deposition following complement activation, and its regulation by CD46 were studied using xenogenic Chinese hamster ovary (CHO) cells as targets and cytofluorometry. Following activation of the alternative pathway, an initial low level of C3b deposition was observed on CHO cell surfaces after a lag time of approximately 4 min. This was followed by a secondary high level of C3b deposition with a slower rate. C3b deposition was maximal within 15 min. When CD46 was expressed (B2 isoform), the kinetics of C3b deposition were essentially unchanged, but the onset of the secondary high C3b deposition was fully prevented. C5b deposition was also observed on CHO but not on CHO.CD46 cells following activation of the alternative pathway. Activation of the classical pathway on CHO and CHO.CD46 cells, using factor B-depleted human serum and anti-CHO antibodies, resulted in almost identical single-peak C3b deposition profiles. Accordingly, no regulation of C5b deposition by CD46 was evident following activation of the classical pathway. These data indicate that CD46 prevents the C3b deposition amplification loop mediated by the alternative C3 convertase and, consequently, inhibits the formation of the alternative C5 convertase. But CD46 prevents neither the spontaneous tick-over C3b deposition leading to the formation of the alternative C3 convertase nor the formation of the functional classical C3 and C5 convertases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092084     DOI: 10.1002/(SICI)1521-4141(199903)29:03<815::AID-IMMU815>3.0.CO;2-8

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.

Authors:  D Christiansen; P Devaux; B Réveil; A Evlashev; B Horvat; J Lamy; C Rabourdin-Combe; J H Cohen; D Gerlier
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Expression of complement regulating factors in gastric cancer cells.

Authors:  T Inoue; M Yamakawa; T Takahashi
Journal:  Mol Pathol       Date:  2002-06

3.  Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Barbara Schraml; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-10-05       Impact factor: 4.407

4.  Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 6.  Inhibiting complement activation on cells at the step of C3 cleavage.

Authors:  M Kathryn Liszewski; Celia J Fang; John P Atkinson
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 7.  Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.

Authors:  Mark A Brockman; David M Knipe
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

8.  Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.

Authors:  Celia J Fang; Veronique Fremeaux-Bacchi; M Kathryn Liszewski; Gaia Pianetti; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Blood       Date:  2007-10-03       Impact factor: 22.113

9.  CD46 protects against chronic obstructive pulmonary disease.

Authors:  Sandra Grumelli; Bao Lu; Leif Peterson; Toshitaka Maeno; Craig Gerard
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

10.  The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.

Authors:  Cinzia Scambi; Sara Ugolini; T Sakari Jokiranta; Lucia De Franceschi; Oscar Bortolami; Valentina La Verde; Patrizia Guarini; Paola Caramaschi; Viviana Ravagnani; Guido Martignoni; Chiara Colato; Serena Pedron; Fabio Benedetti; Marco Sorio; Fabio Poli; Domenico Biasi
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.